A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma

MLA

Kristi Mahadocon, et al. “A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma.” Blood, vol. 112, Nov. 2008, p. 3178. EBSCOhost, https://doi.org/10.1182/blood.v112.11.3178.3178.

APA

Kristi Mahadocon, Steven Coutre, Mary G. Bolton, Peggy Kegley, R. Donald Harvey, David S. Siegel, William Plunkett, Rajni Sinha, Judith A. Fox, Runzhe Chen, Leslie Popplewell, William G. Wierda, & Ashraf Badros. (2008). A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma. Blood, 112, 3178. https://doi.org/10.1182/blood.v112.11.3178.3178

Chicago

Kristi Mahadocon, Steven Coutre, Mary G. Bolton, Peggy Kegley, R. Donald Harvey, David S. Siegel, William Plunkett, et al. 2008. “A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma.” Blood 112 (November): 3178. doi:10.1182/blood.v112.11.3178.3178.